BeStock  
Stocks › ARQT

Arcutis Biotherapeutics ARQT

US equityMarket cap rank #2441
$25.15 −$0.01 (-0.04%)
Pre-market · Oct 6, 7:40 am ET · After hours $25.25 +0.40%
Open$25.09
Prev close$25.16
Day range$24.69 – $25.39
Volume2.31M
Market cap$3.16B
P/E (TTM)114.3
Dividend yield–

ARQT Stock News

Headlines matching Arcutis Biotherapeutics or the ARQT ticker, most recent first.

  • Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common StocksMarket news · 17 Sep 2026
  • A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40Market news · 7 Aug 2026
  • H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34Market news · 11 Aug 2026
  • Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)TipRanks · 11 Aug 2026
  • Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market news · 15 Jul 2026
  • Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36Market news · 1 Jul 2026
  • A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36Market news · 8 May 2026
  • Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)TipRanks · 26 May 2026
  • Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market news · 26 May 2026
  • TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market news · 23 Apr 2026
  • Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35Market news · 22 Apr 2026
  • Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)TipRanks · 22 Apr 2026
  • H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30Market news · 3 Feb 2026
  • Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35Market news · 28 Feb 2026
  • A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37Market news · 27 Feb 2026

Discussion

No comments yet — be the first to weigh in on ARQT.

Leave a comment

Scroll to Top